Jordi Pey - Oryzon Genomics Chief Officer

All Insiders . Spain . 
Stock . Oryzon Genomics SA . Stakeholders . Insider . Jordi Pey
ORY Stock  EUR 1.54  0.02  1.28%   

Insider

Jordi Pey is Chief Officer of Oryzon Genomics SA
Phone34 93 515 13 13
Webhttps://www.oryzon.com

Oryzon Genomics Management Efficiency

The company has return on total asset (ROA) of (0.0419) % which means that it has lost $0.0419 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.0685) %, meaning that it generated substantial loss on money invested by shareholders. Oryzon Genomics' management efficiency ratios could be used to measure how well Oryzon Genomics manages its routine affairs as well as how well it operates its assets and liabilities.
Oryzon Genomics SA has accumulated 10.35 M in total debt with debt to equity ratio (D/E) of 37.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Oryzon Genomics SA has a current ratio of 2.68, suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due. Debt can assist Oryzon Genomics until it has trouble settling it off, either with new capital or with free cash flow. So, Oryzon Genomics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Oryzon Genomics SA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Oryzon to invest in growth at high rates of return. When we think about Oryzon Genomics' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

INSIDER Age

Alfredo PeaENCE Energa y
56
Jesus CollazosViscofan
N/A
Jos IrurzunViscofan
N/A
Juan RotaViscofan
N/A
Juan ArrietaViscofan
N/A
Fernando GonzalezPalaciosENCE Energa y
N/A
Irene AlvarezENCE Energa y
N/A
Maria SolisEbro Foods
N/A
Pablo SolsEbro Foods
N/A
Rul MerinoVidrala SA
N/A
Faustino RodriguezENCE Energa y
N/A
Andrs EchevarraViscofan
N/A
Alberto ValdesENCE Energa y
N/A
Marc FerretENCE Energa y
N/A
Wilfried SchobelViscofan
N/A
Guillermo EguidazuViscofan
N/A
Mara RuizViscofan
N/A
Modesto SuarezENCE Energa y
N/A
Alejandro BergazViscofan
N/A
Alfonso BarrEbro Foods
N/A
Amaia TelleriaENCE Energa y
N/A
Oryzon Genomics S.A., a clinical stage biopharmaceutical company, discovers and develops epigenetic therapies to treat oncology and neurodegenerative diseases. Oryzon Genomics S.A. was founded in 2000 and is based in Barcelona, Spain. ORYZON GENOMICS operates under Biotechnology classification in Spain and is traded on Madrid SE C.A.T.S.. It employs 40 people. Oryzon Genomics SA (ORY) is traded on Madrid Exchange in Spain and employs 43 people.

Management Performance

Return On Equity-0.0685
Return On Asset-0.0419

Oryzon Genomics SA Leadership Team

Elected by the shareholders, the Oryzon Genomics' board of directors comprises two types of representatives: Oryzon Genomics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Oryzon. The board's role is to monitor Oryzon Genomics' management team and ensure that shareholders' interests are well served. Oryzon Genomics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Oryzon Genomics' outside directors are responsible for providing unbiased perspectives on the board's policies.
Saikat Nandi, Global Officer
Emili Cortada, Chief Officer
Enric Condomines, Director of Finance and Operations
Xavier Ribera, Head Compliance
Michael Ropacki, Chief CNS
Sonia Bezon, Chief Operations
Jordi Pey, Chief Officer
Ana Limon, Sr Affairs
Carlos Arjol, Chairman of the Board
Neus Bernado, Chief Officer

Oryzon Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Oryzon Genomics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity-0.0685
Return On Asset-0.0419
Profit Margin(0.33) %
Operating Margin(0.72) %
Current Valuation107.12 M
Shares Outstanding55.56 M
Shares Owned By Insiders18.04 %
Shares Owned By Institutions0.72 %
Price To Earning(12.98) X
Price To Book1.65 X

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
RSIRush Street Interactive
OKTAOkta Inc
BACBank of America

Other Information on Investing in Oryzon Stock

Oryzon Genomics financial ratios help investors to determine whether Oryzon Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Oryzon with respect to the benefits of owning Oryzon Genomics security.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY